There will be better protection against severe disease, hospitalization, and death from COVID-19 in the coming months now that newly updated (2023–2024 formula) mRNA COVID vaccines are available. The new shots are…
Drug Name: Relyvrio Active Ingredient: sodium phenylbutyrate/taurursodiol Indications: To treat amyotrophic lateral sclerosis (ALS) Approval Date: 9/29/2022 Company: Amylyx Pharmaceuticals, Inc Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216660s000lbledt.pdf
Drug Name: Lytgobi Active Ingredient: futibatinib Indications: To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements Approval Date: 9/30/2022 Company: Taiho Oncology, Inc…
Drug Name: Omlonti Active Ingredient: oomidenepag isopropyl ophthalmic solution Indications: To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension Approval Date: 9/22/2022 Company: Santen Incorporated…
Drug Name: Terlivaz Active Ingredient: terlipressin Indications: To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function Approval Date: 9/14/2022 Company: Mallinckrodt Hospital Products Inc…
Drug Name: Sotyktu Active Ingredient: deucravacitinib Indications: To treat moderate-to-severe plaque psoriasis Approval Date: 9/9/2022 Company: Bristol-Myers Squibb Company Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf
Drug Name: Rolvedon Active Ingredient: eflapegrastim Indications: To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia…
Drug Name: Daxxify Active Ingredient: daxibotulinumtoixnA-lanm Indications: To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity. Approval Date: 9/7/2022 Company: Revance Therapeutics, Inc Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761127s000lbl.pdf
Drug Name: Spevigo Active Ingredient: spesolimab-sbzo Indications: To treat generalized pustular psoriasis flares Approval Date: 9/1/2022 Company: Boehringer Ingelheim International GmbH Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf
Drug Name: Xenpozyme Active Ingredient: Olipudase alfa Indications: To treat Acid Sphingomyelinase Deficiency (ASD) Approval Date: 8/31/2022 Company: Genzyme Corporation Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761261s000lbl.pdf